Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dormant virus wakes in the ICU: can CMV reactivation explain worse outcomes on ventilators?

NCT ID NCT06520605

Knowledge-focused Sponsor: Sanjay Gandhi Postgraduate Institute of Medical Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 20, 2026 · Last updated Oct 21, 2026 · Updated 1 time

Summary

Cytomegalovirus (CMV) stays dormant in most people but can reactivate during severe illness, even in patients without a weakened immune system. Researchers are observing adults in intensive care who need mechanical ventilation for at least seven days and who carry CMV antibodies. The study measures how often the virus reactivates, how much virus is present, and whether higher viral loads track with more severe illness. No antiviral treatment is given; the goal is to understand the virus's behavior in this group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the study links CMV reactivation to worse illness in ventilated patients, it could guide future trials of antiviral treatment or closer viral monitoring in intensive care.
What could go wrong
This is an observational study with no treatment, so it cannot show whether CMV causes harm or whether treating it helps. Findings from one hospital's ICU may not apply elsewhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

117 people

The number who actually took part.

Started

Jul 2024

Finished

Apr 2026

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All adult ICU patients requiring prolonged mechanically ventilation (at least 7 days of supportive ventilation) and the presence of CMV seropositivity (Anti CMV IgG antibodies) will be screened for the possible inclusion.

Ages

18 to 80 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All adult ICU patients requiring prolonged mechanically ventilation (at least 7 days of supportive ventilation) and the presence of CMV seropositivity (Anti CMV IgG antibodies) will be considered for inclusion Exclusion Criteria: * Age \<18 years * Use of anti viral agent within last 7 days * Duration of mechanical ventilation more than 14 days before the admission to our ICU * Known or suspected underlying immune deficiency (history of solid organ or stem cell transplantation, infection with human immunodeficiency virus, haematological malignancy, use of immunosuppressive medication (more than 0.1 mg /kg prednisone for \>3 months, more than 1 mg/kg/day prednisone for \>3 weeks or equivalent), chemotherapy/ radiotherapy in the year before ICU admission and any known humeral or cellular immune deficiency. * Pregnancy * Patient who do not consent for study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mechanical ventilation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Critical Illness

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mechanical ventilation

Contacts and locations

Locations

  • Sanjay Gandhi Postgraduate Institute of Medical Sciences

    Lucknow, Uttar Pradesh, 226014, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.